These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22186077)

  • 21. A comparative study of adverse drug reactions during two heat waves that occurred in France in 2003 and 2006.
    Sommet A; Durrieu G; Lapeyre-Mestre M; Montastruc JL;
    Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):285-8. PubMed ID: 22162094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Official systems of pharmacovigilance in France and in Spain. Comparison of spontaneous reporting in two regional centers: Pays Basque and Bordeaux].
    Aguirre C; Haramburu F
    Therapie; 1995; 50(6):563-9. PubMed ID: 8745957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An updated method improved the assessment of adverse drug reaction in routine pharmacovigilance.
    Théophile H; André M; Arimone Y; Haramburu F; Miremont-Salamé G; Bégaud B
    J Clin Epidemiol; 2012 Oct; 65(10):1069-77. PubMed ID: 22910538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Causality assessment in pharmacovigilance: The French method and its successive updates.
    Miremont-Salamé G; Théophile H; Haramburu F; Bégaud B
    Therapie; 2016 Apr; 71(2):179-86. PubMed ID: 27080836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Use of the capture-recapture method to assess the frequency of "serious" adverse drug reactions: experience of Toulouse University Hospital].
    Montastruc JL; Lugardon S; Desboeuf K; Fernet P; Lapeyre-Mestre M
    Bull Acad Natl Med; 2008 Feb; 192(2):421-30; discussion 430-1. PubMed ID: 18819693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
    Olivier P; Montastruc JL
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Grouping the pharmacovigilance terms with a hybrid approach.
    Dupuch M; Dupuch L; Perinet A; Hamon T; Grabar N
    Stud Health Technol Inform; 2012; 180():235-9. PubMed ID: 22874187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Iatrogenic medication: estimation of its prevalence in French public hospitals. Regional Centers of Pharmacovigilance].
    Imbs JL; Pouyanne P; Haramburu F; Welsch M; Decker N; Blayac JP; Bégaud B
    Therapie; 1999; 54(1):21-7. PubMed ID: 10216418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation and Reproducibility of the Updated French Causality Assessment Method: an Evaluation by Pharmacovigilance Centres & Pharmaceutical Companies.
    Théophile H; Dutertre JP; Gérardin M; Valnet-Rabier MB; Bidault I; Guy C; Haramburu F; Hillaire-Buys D; Méglio C; Arimone Y
    Therapie; 2015; 70(5):465-76. PubMed ID: 26423144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Organisation of clinical research in France: the new missions of inter-regional delegations for clinical research].
    Jaillon P
    Bull Acad Natl Med; 2008 May; 192(5):929-37; discussion 937-9. PubMed ID: 19238783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Good practices of publication of clinical cases of pharmacovigilance: comments, Groupe de Travail sur les Bonnes Pratiques de Publication de Cliniques en Pharmacovigilance: commentary].
    Auriche M; Bertrand P; Blay N; Danan G; Hamel JD; Imbs JL; Lagier G; Micaleff A; Moore N; Ollagnier M; Reveilleau-Richard S; Soubrié C; Weber F
    Therapie; 1997; 52(2):123-7. PubMed ID: 9231506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perioperative platelet transfusion: recommendations of the Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSaPS) 2003.
    Samama CM; Djoudi R; Lecompte T; Nathan-Denizot N; Schved JF;
    Can J Anaesth; 2005 Jan; 52(1):30-7. PubMed ID: 15625253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Drug vigilance].
    Imbs JL; Welsch M
    Rev Prat; 2002 Mar; 52(5):502-6. PubMed ID: 11949502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Terappel: description of a computerised database and examples of studies].
    Vial T; Gouraud A; Bernard N
    Therapie; 2014; 69(1):31-8. PubMed ID: 24698186
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: a win-win bet with Health Authorities!].
    Jonville-Bera AP; Gautier S; Micallef J; Massy N; Atzenhoffer M; Drici MD; Grandvuillemin A;
    Therapie; 2023; 78(5):477-488. PubMed ID: 36890032
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Joint program of pharmacovigilance in Quebec: comparison with France, Aquitaine and the Basque region].
    Biron P; Balency D
    Therapie; 1996; 51(5):578-81. PubMed ID: 9138400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacovigilance as new direction of research].
    Gaszner G; Makkos Z; Gaszner P
    Neuropsychopharmacol Hung; 2005 Dec; 7(4):194-8. PubMed ID: 16496484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. European Court of Justice. ECJ 2014/6 Octapharma France SAS v. Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), Ministère des Affaires Sociales et de la Santé, 13 March 2014 (C-512/12).
    Baeyens A; Goffin T
    Eur J Health Law; 2014 Jun; 21(3):317-21. PubMed ID: 25065041
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.